Take a look at this month’s industry headlines including US FDA approvals for two drugs – Xenleta™ and Pretomanid – in addition to an EMA decision for Zerbaxa®, partnerships for vaccine development and results on Ebola therapeutics.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new…
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
A large-scale trial of RTS,S – the world’s first malaria vaccine to provide partial protection – is due to commence in Malawi, Kenya and Ghana.
